research use only
Cat.No.S9555
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Microtubule Associated Inhibitors | Nocodazole Patupilone (Epothilone B) CW069 Combretastatin A4 Lexibulin (CYT997) Epothilone A ABT-751 (E7010) Cucurbitacin B TRx0237 (LMTX) mesylate DM1 (Mertansine) |
|
In vitro |
DMSO
: 100 mg/mL
(121.21 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 824.96 | Formula | C46H56N4O10 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 57-22-7 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| In vitro |
This compound, a microtubule-destabilizing agent (MDA), inhibits the formation of microtubules and mitosis of the cancer cell, which is a victim of intratumoural metabolic resistance that has no important relevance with neither CYP3A4 nor CYP3A5. |
|---|---|
| In vivo |
This compound shows the regression of the tumor in zebrafish xenografts. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-06-11)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07220187 | NOT_YET_RECRUITING | Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma |
SWOG Cancer Research Network |
2026-08-31 | PHASE3 |
| NCT07072585 | NOT_YET_RECRUITING | Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
Children's Oncology Group |
2026-08-28 | PHASE2; PHASE3 |
| NCT04681417 | RECRUITING | Retinoblastoma |
Institut Curie |
2021-03-25 | PHASE2; PHASE3 |
| NCT07724457 | NOT_YET_RECRUITING | Recurrent Burkitt Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory Burkitt Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements |
National Cancer Institute (NCI) |
2026-10-30 | PHASE2; PHASE3 |
| NCT07387926 | RECRUITING | Acute Lymphoblastic Leukemia; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Novartis Pharmaceuticals |
2026-07-05 | PHASE1; PHASE2 |
| NCT04307576 | RECRUITING | Leukemia, Acute Lymphoblastic |
Mats Heyman |
2020-07-13 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.